APTOF | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

3.77%

1 Month

-30.16%

3 Months

-30.16%

6 Months

-30.16%

1 Year

-30.16%

2 Year

-30.16%

Key data

Stock price

$2.20

P/E Ratio

N/A

DAY RANGE

$2.20 - $2.23

EPS

N/A

52 WEEK RANGE

$1.10 - $4.00

52 WEEK CHANGE

-$30.16

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$11,873

AVERAGE 30 VOLUME

$50,410

Company detail

CEO: William G. Rice
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.

APTOF - Aptose Biosciences Inc.